Madrigal Pharmaceuticals (NASDAQ:MDGL) vs. Xilio Therapeutics (NASDAQ:XLO) Head to Head Survey

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Xilio Therapeutics (NASDAQ:XLO) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends and institutional ownership.

Earnings & Valuation

This table compares Madrigal Pharmaceuticals and Xilio Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$180.13 million	40.12	-$373.63 million	($22.11)	-14.80
Xilio Therapeutics	$4.62 million	7.85	-$76.40 million	($1.72)	-0.48

Xilio Therapeutics has lower revenue, but higher earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Madrigal Pharmaceuticals and Xilio Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	N/A	-71.78%	-53.25%
Xilio Therapeutics	N/A	-211.50%	-80.31%

Insider & Institutional Ownership

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are owned by institutional investors. 22.8% of Madrigal Pharmaceuticals shares are owned by company insiders. Comparatively, 5.2% of Xilio Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations for Madrigal Pharmaceuticals and Xilio Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1	1	10	1	2.85
Xilio Therapeutics	0	0	1	0	3.00

Madrigal Pharmaceuticals currently has a consensus target price of $375.75, indicating a potential upside of 14.80%. Xilio Therapeutics has a consensus target price of $4.00, indicating a potential upside of 384.85%. Given Xilio Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Xilio Therapeutics is more favorable than Madrigal Pharmaceuticals.

Risk & Volatility

Madrigal Pharmaceuticals has a beta of -0.41, meaning that its share price is 141% less volatile than the S&P 500. Comparatively, Xilio Therapeutics has a beta of -0.38, meaning that its share price is 138% less volatile than the S&P 500.

Summary

Madrigal Pharmaceuticals beats Xilio Therapeutics on 8 of the 14 factors compared between the two stocks.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

About Xilio Therapeutics

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.